PILOT-STUDY FOR PREOPERATIVE ADMINISTRATION OF L-OHP TO PATIENTS WITHADVANCED SCIRRHOUS TYPE GASTRIC-CANCER

A new DACH platinum complex, 1-OHP, was developed by Kidani as an anti cancer agent. A clinical trial took place in Europe which demonstrated its therapeutic efficacy for colorectal cancer. An effective treatmen t, especially chemotherapy for patients with advanced scirrhous type g astric cancer, has not yet been established. An in vitro study showed that 1-OHP inhibited cell growth in human gastric cancer cell lines. O ur pilot study determined the efficacy of preoperative administration of 1-OHP, 67 mg/m(2) to 100 mg/m(2), every 2-3 weeks, for two to three cycles, in five patients with this disease (Stage III and IV) roentog enoscopically and histologically. The platinum concentration in the ti ssues was also measured. By X-ray examination of the stomach at the ti me of pre- and post-administration of 1-OHP, extension of the lesional gastric wall was observed. Histologically three Grade 2 responses and two Grade la responses were obtained according to the criteria presen ted by Japanese Research Society for Gastric Cancer. The mean platinum concentrations in the lesional tissues were 0.98 ppm and 0.5 ppm in t he patients administered 1-OHP for three and two cycles respectively. There was no toxicity that prevented surgery. These preliminary result s showed the possibility that 1-OHP would be effective for patients wi th advanced scirrhous type gastric cancer as a neoadjuvant therapy.